Clinical Trial Update: Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating CD19-directed CAR T-cells with dual co-stimulatory 4-1BB and CD3ζ domains in relapsed/refractory aggressive non-Hodgkin lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19-directed CAR T-cell therapy with 4-1BB and CD3ζ co-stimulatory domains (CD19-directed CAR T cells with 4-1BB/CD3ζ co-stimulation)

Snippet

Sponsor: University of Alberta | Conditions: Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL | Phase 1, Phase 2 | Status: RECRUITING